Compare CAVA Group Inc (CAVA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CAVA Group Inc vs Novo Nordisk A/S — how do they compare? CAVA Group Inc trades at $72.2 (market cap $8.15B), while Novo Nordisk A/S trades at $48.93 (market cap $214.94B). The key difference: Novo Nordisk A/S is far larger — about 26.4× CAVA Group Inc's market cap, and Novo Nordisk A/S pays a 3.67% dividend while CAVA Group Inc pays none. Which is the better fit depends on your goals.
| CAVA | NVO | |
|---|---|---|
Market Cap | $8.15B | $214.94B |
Sector | Consumer Cyclical | Health |
52-Week High | $97.39 | $71.70 |
52-Week Low | $43.59 | $35.29 |
Enterprise Value | $8.25B | $233.91B |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CAVA trades at $72.54, up 0.5% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong revenue growth and expansion momentum, but faces high valuation multiples and margin pressures. Recent news highlights aggressive store openings and technology investments driving traffic, though the stock has experienced volatility amid market fluctuations.
Outlook remains growth-focused with analyst consensus bullish, targeting $94.73, but risks include elevated P/E of 134.56, competitive pressures, and potential margin compression from expansion costs. The stock offers upside if execution continues, but requires careful monitoring of profitability trends.
Novo Nordisk (NVO) trades at $49.28, down 0.4% on the day, with strong technical momentum indicated by bullish moving averages and a neutral RSI near 63. The company demonstrates robust fundamentals with a P/E of 11.83, net income margin of 37.2%, and consistent earnings beats in recent quarters. Recent news highlights competitive strength in GLP-1 drugs, including Wegovy pill adoption outpacing Eli Lilly's offering.
Outlook remains positive given analyst consensus of 57.9% buy ratings and intrinsic value estimates near $90, though risks include prescription slowdown concerns and rising debt-to-asset ratios. The stock presents a growth opportunity in pharmaceuticals with manageable near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CAVA Group Inc
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
